S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Clovis Oncology (CLVS) Stock Forecast, Price & News

+0.02 (+2.69%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
3.82 million shs
Average Volume
9.70 million shs
Market Capitalization
$112.44 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

Clovis Oncology logo

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$148.76 million
Book Value
($2.15) per share


Net Income
$-264.52 million
Net Margins
Pretax Margin




Free Float
Market Cap
$112.44 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.80 out of 5 stars

Medical Sector

804th out of 1,403 stocks

Pharmaceutical Preparations Industry

393rd out of 667 stocks

Analyst Opinion: 3.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

Is Clovis Oncology a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View analyst ratings for Clovis Oncology
or view top-rated stocks.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Clovis Oncology

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.01. During the same period in the prior year, the company earned ($0.64) earnings per share.
View Clovis Oncology's earnings history

What price target have analysts set for CLVS?

2 brokerages have issued 1-year target prices for Clovis Oncology's shares. Their forecasts range from $4.75 to $5.00. On average, they anticipate Clovis Oncology's share price to reach $4.88 in the next year. This suggests a possible upside of 523.8% from the stock's current price.
View analysts' price targets for Clovis Oncology
or view top-rated stocks among Wall Street analysts.

Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64) (LinkedIn Profile)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.58%), Renaissance Technologies LLC (1.01%), Northern Trust Corp (0.77%), Charles Schwab Investment Management Inc. (0.65%), Panagora Asset Management Inc. (0.40%) and Qube Research & Technologies Ltd (0.34%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends for Clovis Oncology

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Sculptor Capital LP, Principal Financial Group Inc., Northern Trust Corp, Group One Trading L.P., SG Americas Securities LLC, and Wolverine Asset Management LLC. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding.
View insider buying and selling activity for Clovis Oncology
or view top insider-selling stocks.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Qube Research & Technologies Ltd, Nisa Investment Advisors LLC, XTX Topco Ltd, Dupont Capital Management Corp, WINTON GROUP Ltd, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Clovis Oncology
or or view top insider-buying stocks.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $0.78.

How much money does Clovis Oncology make?

Clovis Oncology has a market capitalization of $112.44 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264.52 million in net income (profit) each year or ($2.110010) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at [email protected], or via fax at 303-245-0360.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.